Recent advances in the pharmacological management of sepsis-associated acute kidney injury

References

• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Sakr Y, Jaschinski U, Wittebole X, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5(12):ofy313.
   PubMed Web of Science ®Google Scholar
• PeerapornratanaS, Manrique-Caballero CL, Gómez H, et al. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96(5):1083–1099.
   PubMed Web of Science ®Google Scholar
• Peters E, Antonelli M, Wittebole X, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the intensive care over nations audit. Crit Care. 2018;22(1):188.
   PubMedGoogle Scholar
• Bagshaw SM, George C, Bellomo R, et al. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12(2):R47.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Lefrant J-Y, Kotfis K, et al. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Intensive Care Med. 2018;44(3):337–344.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
   PubMed Web of Science ®Google Scholar
• Doi K, Yuen PST, Eisner C, et al. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol. 2009;20(6):1217–1221.
   PubMed Web of Science ®Google Scholar
• Nickolas TL, O’Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810–819.
   PubMed Web of Science ®Google Scholar
• Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231–1238.
   PubMed Web of Science ®Google Scholar
• Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752–1761.
   PubMed Web of Science ®Google Scholar
• Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis. 2008;52(3):425–433.
   PubMed Web of Science ®Google Scholar
• Tornblom S, Nisula S, Petäjä L, et al. Urine NGAL as a biomarker for septic AKI: a critical appraisal of clinical utility—data from the observational FINNAKI study. Ann Intensive Care. 2020;10(1):51.
   PubMed Web of Science ®Google Scholar
• Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.
   PubMed Web of Science ®Google Scholar
• Hoste EA, Vaara ST, De Loor J, et al. Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort. Crit Care. 2020;24(1):144.
   PubMed Web of Science ®Google Scholar
• Gayat E, Touchard C, Hollinger A, et al. Back-to-back comparison of penKID with NephroCheck® to predict acute kidney injury at admission in intensive care unit: a brief report. Crit Care. 2018;22(1):24.
   PubMedGoogle Scholar
• Bagshaw SM, Haase M, Haase-Fielitz A, et al. A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. Nephrol Dial Transplant. 2012;27(2):582–588.
   PubMed Web of Science ®Google Scholar
• Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382(9887):170–179.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Knight R, Appelbaum PS, et al. Integrating patient priorities with science by community engagement in the kidney precision medicine project. Clin J Am Soc Nephrol. 2021 Apr 7;16(4):660-668.
   Google Scholar
• Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure. Kidney Int. 2006;69(11):1996–2002.
   PubMed Web of Science ®Google Scholar
• Prowle JR, Molan MP, Hornsey E, et al. Measurement of renal blood flow by phase-contrast magnetic resonance imaging during septic acute kidney injury: a pilot investigation. Crit Care Med. 2012;40(6):1768–1776.
   PubMed Web of Science ®Google Scholar
• Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41(1):3–11.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Leopold SJ, Cranendonk DR, et al. Host innate immune responses to sepsis. Virulence. 2014;5(1):36–44.
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21(1):335–376.
   PubMed Web of Science ®Google Scholar
• Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29(4):617–25, viii.
   PubMed Web of Science ®Google Scholar
• Lerolle N, Nochy D, Guérot E, et al. Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med. 2010;36(3):471–478.
   PubMed Web of Science ®Google Scholar
• Aslan A, van den Heuvel MC, Stegeman CA, et al. Kidney histopathology in lethal human sepsis. Crit Care. 2018;22(1):359.
   PubMedGoogle Scholar
• Roger T, David J, Glauser MP, et al. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature. 2001;414(6866):920–924.
   PubMed Web of Science ®Google Scholar
• Weber C, Kraemer S, Drechsler M, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci U S A. 2008;105(42):16278–16283.
   PubMed Web of Science ®Google Scholar
• Payen D, Lukaszewicz A-C, Legrand M, et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. PLoS One. 2012;7(6):e35838.
   PubMed Web of Science ®Google Scholar
• Unruh M, Wagner B, Hallows KR. MIF matters: the macrophage migration inhibitory factor and kidney injury. Am J Kidney Dis. 2019;73(3):429–431.
   PubMed Web of Science ®Google Scholar
• Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000;6(2):164–170.
   PubMed Web of Science ®Google Scholar
• Kockara A, Kayatas M. Renal cell apoptosis and new treatment options in sepsis-induced acute kidney injury. Ren Fail. 2013;35(2):291–294.
   PubMed Web of Science ®Google Scholar
• Jacobs R, Honore PM, Joannes-Boyau O, et al. Septic acute kidney injury: the culprit is inflammatory apoptosis rather than ischemic necrosis. Blood Purif. 2011;32(4):262–265.
   PubMed Web of Science ®Google Scholar
• Guo R, Wang Y, Minto AW, et al. Acute renal failure in endotoxemia is dependent on caspase activation. J Am Soc Nephrol. 2004;15(12):3093–3102.
   PubMed Web of Science ®Google Scholar
• Lee SY, Lee Y-S, Choi H-M, et al. Distinct pathophysiologic mechanisms of septic acute kidney injury: role of immune suppression and renal tubular cell apoptosis in murine model of septic acute kidney injury. Crit Care Med. 2012;40(11):2997–3006.
   PubMed Web of Science ®Google Scholar
• Kalakeche R, Hato T, Rhodes G, et al. Endotoxin uptake by S1 proximal tubular segment causes oxidative stress in the downstream S2 segment. J Am Soc Nephrol. 2011;22(8):1505–1516.
   PubMed Web of Science ®Google Scholar
• Nakano D, Doi K, Kitamura H, et al. Reduction of tubular flow rate as a mechanism of Oliguria in the early phase of endotoxemia revealed by intravital imaging. J Am Soc Nephrol. 2015;26(12):3035–3044.
   PubMed Web of Science ®Google Scholar
• Peters E, Masereeuw R, Pickkers P. The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injury. Nephron Clin Pract. 2014;127(1–4):144–148.
   PubMedGoogle Scholar
• Sullivan GW, Fang G, Linden J, et al. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis. 2004;189(10):1897–1904.
   PubMed Web of Science ®Google Scholar
• Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37(2):417–23, e1.
   PubMed Web of Science ®Google Scholar
• Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16(1):R14.
   PubMed Web of Science ®Google Scholar
• Pickkers P, Mehta RL, Murray PT, et al. Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. JAMA. 2018;320(19):1998–2009.
   PubMed Web of Science ®Google Scholar
• (Revival) study to investigate the efficacy and safety of alkaline phosphatase in patients with sepsis-associated AKI. [cited 2021 Jul 3]. Available from: https://ClinicalTrials.gov/show/NCT04411472
   Google Scholar
• Bulger EM, May AK, Robinson BRH, et al. A novel immune modulator for patients with necrotizing soft tissue infections (NSTI): results of a multicenter, phase 3 randomized controlled trial of reltecimod (AB 103). Ann Surg. 2020;272(3):469–478.
   PubMed Web of Science ®Google Scholar
• Ala-Kokko TI, Laurila J, Koskenkari J. A new endotoxin adsorber in septic shock: observational case series. Blood Purif. 2011;32(4):303–309.
   PubMed Web of Science ®Google Scholar
• Monard C, Rimmele T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(Suppl 3):1–14.
   Google Scholar
• Comparing cytokines, toxins adsorbing oXiris filter to ST150 filter during CRRT in patients with septic shock. [cited 2021 Jul 3]. Available from: https://ClinicalTrials.gov/show/NCT02600312
   Google Scholar
• Asfar P, Meziani F, Hamel J-F, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583–1593.
   PubMed Web of Science ®Google Scholar
• De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789.
   PubMed Web of Science ®Google Scholar
• Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008;12(6):R143.
   PubMed Web of Science ®Google Scholar
• Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226–2234.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–518.
   PubMed Web of Science ®Google Scholar
• De Backer D, Aldecoa C, Njimi H, et al. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis• . Crit Care Med. 2012;40(3):725–730.
   PubMed Web of Science ®Google Scholar
• Laterre PF, Berry SM, Blemings A, et al. Effect of Selepressin vs Placebo on ventilator- and vasopressor-free days in patients with septic shock: the SEPSIS-ACT randomized clinical trial. JAMA. 2019;322(15):1476.
   PubMed Web of Science ®Google Scholar
• Wan L, Langenberg C, Bellomo R, et al. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13(6):R190.
   PubMed Web of Science ®Google Scholar
• Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–430.
   PubMed Web of Science ®Google Scholar
• Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949–957.
   PubMed Web of Science ®Google Scholar
• Leisman DE, Fernandes TD, Bijol V, et al. Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury. Kidney Int. 2021;99(1):148–160.
   PubMed Web of Science ®Google Scholar
• De Backer D, Creteur J, Preiser J-C, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166(1):98–104.
   PubMed Web of Science ®Google Scholar
• Edul VS, Enrico C, Laviolle B, et al. Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Crit Care Med. 2012;40(5):1443–1448.
   PubMed Web of Science ®Google Scholar
• Sakr Y, Dubois M-J, De Backer D, et al. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32(9):1825–1831.
   PubMed Web of Science ®Google Scholar
• Trzeciak S, McCoy JV, Phillip Dellinger R, et al. Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis. Intensive Care Med. 2008;34(12):2210–2217.
   PubMed Web of Science ®Google Scholar
• De Backer D, Donadello K, Taccone FS, et al. Microcirculatory alterations: potential mechanisms and implications for therapy. Ann Intensive Care. 2011;1(1):27.
   PubMedGoogle Scholar
• Xu C, Chang A, Hack BK, et al. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis. Kidney Int. 2014;85(1):72–81.
   PubMed Web of Science ®Google Scholar
• Ospina-Tascon G, Neves AP, Occhipinti G, et al. Effects of fluids on microvascular perfusion in patients with severe sepsis. Intensive Care Med. 2010;36(6):949–955.
   PubMed Web of Science ®Google Scholar
• Post EH, Kellum JA, Bellomo R, et al. Renal perfusion in sepsis: from macro- to microcirculation. Kidney Int. 2017;91(1):45–60.
   PubMed Web of Science ®Google Scholar
• Wu L, Gokden N, Mayeux PR. Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. J Am Soc Nephrol. 2007;18(6):1807–1815.
   PubMed Web of Science ®Google Scholar
• Holthoff JH, Wang Z, Seely KA, et al. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 2012;81(4):370–378.
   PubMed Web of Science ®Google Scholar
• Johannes T, Mik EG, Klingel K, et al. Effects of 1400W and/or nitroglycerin on renal oxygenation and kidney function during endotoxaemia in anaesthetized rats. Clin Exp Pharmacol Physiol. 2009;36(9):870–879.
   PubMed Web of Science ®Google Scholar
• Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ. 2019;364:k4891.
   PubMedGoogle Scholar
• Morelli A, Donati A, Ertmer C, et al. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care. 2010;14(6):R232.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375(17):1638–1648.
   PubMed Web of Science ®Google Scholar
• Che R, Yuan Y, Huang S, et al. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2014;306(4):F367–78.
   PubMed Web of Science ®Google Scholar
• Weinberg JM. Mitochondrial biogenesis in kidney disease. J Am Soc Nephrol. 2011;22(3):431–436.
   PubMed Web of Science ®Google Scholar
• Hato T, Winfree S, Day R, et al. Two-photon intravital fluorescence lifetime imaging of the kidney reveals cell-type specific metabolic signatures. J Am Soc Nephrol. 2017;28(8):2420–2430.
   PubMed Web of Science ®Google Scholar
• Gomez H, Kellum JA, Ronco C. Metabolic reprogramming and tolerance during sepsis-induced AKI. Nat Rev Nephrol. 2017;13(3):143–151.
   PubMed Web of Science ®Google Scholar
• Patil NK, Parajuli N, MacMillan-Crow LA, et al. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. Am J Physiol Renal Physiol. 2014;306(7):F734–43.
   PubMed Web of Science ®Google Scholar
• Horvath SE, Daum G. Lipids of mitochondria. Prog Lipid Res. 2013;52(4):590–614.
   PubMed Web of Science ®Google Scholar
• Dudek J. Role of cardiolipin in mitochondrial signaling pathways. Front Cell Dev Biol. 2017;5:90.
   PubMed Web of Science ®Google Scholar
• Yin H, Zhu M. Free radical oxidation of cardiolipin: chemical mechanisms, detection and implication in apoptosis, mitochondrial dysfunction and human diseases. Free Radic Res. 2012;46(8):959–974.
   PubMed Web of Science ®Google Scholar
• Gai Z, Gui T, Kullak-Ublick GA, et al. The role of mitochondria in drug-induced kidney injury. Front Physiol. 2020;11:1079.
   PubMed Web of Science ®Google Scholar
• Shekhova E, Kniemeyer O, Brakhage AA. Induction of mitochondrial reactive oxygen species production by itraconazole, terbinafine, and amphotericin b as a mode of action against aspergillus fumigatus. Antimicrob Agents Chemother. 2017;61(11).
   PubMed Web of Science ®Google Scholar
• Kaguni LS. DNA polymerase gamma, the mitochondrial replicase. Annu Rev Biochem. 2004;73(1):293–320.
   PubMedGoogle Scholar
• Lemaire M. Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology. Am J Physiol Renal Physiol. 2021;320(2):F145–F160.
   PubMed Web of Science ®Google Scholar
• Ishimoto Y, Inagi R. Mitochondria: a therapeutic target in acute kidney injury. Nephrol Dial Transplant. 2016;31(7):1062–1069.
   PubMed Web of Science ®Google Scholar
• Tabara LC, Poveda J, Martin-Cleary C, et al. Mitochondria-targeted therapies for acute kidney injury. Expert Rev Mol Med. 2014;16:e13.
   PubMed Web of Science ®Google Scholar
• Szeto HH. Pharmacologic approaches to improve mitochondrial function in AKI and CKD. J Am Soc Nephrol. 2017;28(10):2856–2865.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Shi J, Dai W. New therapies for reducing post-myocardial left ventricular remodeling. Ann Transl Med. 2015;3(2):20.
   PubMed Web of Science ®Google Scholar
• Zhao K, Zhao G-M, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682–34690.
   PubMed Web of Science ®Google Scholar
• Cho J, Won K, Wu D, et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18(3):215–220.
   PubMed Web of Science ®Google Scholar
• de Barcelos IP, Emmanuele V, Hirano M. Advances in primary mitochondrial myopathies. Curr Opin Neurol. 2019;32(5):715–721.
   PubMed Web of Science ®Google Scholar
• Eirin A, Li Z, Zhang X, et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension. 2012;60(5):1242–1249.
   PubMed Web of Science ®Google Scholar
• Saad A, Herrmann SMS, Eirin A, et al. Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circ Cardiovasc Interv. 2017;10(9).
   PubMed Web of Science ®Google Scholar
• Ralto KM, Rhee EP, Parikh SM. NAD(+) homeostasis in renal health and disease. Nat Rev Nephrol. 2020;16(2):99–111.
   PubMed Web of Science ®Google Scholar
• Mouchiroud L, Houtkooper RH, Auwerx J. NAD(+) metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol. 2013;48(4):397–408.
   PubMed Web of Science ®Google Scholar
• Martin DR, Lewington AJ, Mannerman MR, et al. Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am J Physiol Regul Integr Comp Physiol. 2000;279(5):R1834–40.
   PubMed Web of Science ®Google Scholar
• Liu S-B, Liu J, Liu D-W, et al. Inhibition of poly-(ADP-ribose) polymerase protects the kidney in a canine model of endotoxic shock. Nephron. 2015;130(4):281–292.
   PubMed Web of Science ®Google Scholar
• Zheng J, Devalaraja-Narashimha K, Singaravelu K, et al. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol. 2005;288(2):F387–98.
   PubMed Web of Science ®Google Scholar
• Rasbach KA, Schnellmann RG. Signaling of mitochondrial biogenesis following oxidant injury. J Biol Chem. 2007;282(4):2355–2362.
   PubMed Web of Science ®Google Scholar
• Tran MT, Zsengeller ZK, Berg AH, et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. 2016;531(7595):528–532.
   PubMed Web of Science ®Google Scholar
• Tran M, Tam D, Bardia A, et al. PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest. 2011;121(10):4003–4014.
   PubMed Web of Science ®Google Scholar
• Dumesic PA, Egan DF, Gut P, et al. An evolutionarily conserved uORF regulates PGC1α and oxidative metabolism in mice, flies, and bluefin tuna. Cell Metab. 2019;30(1):190–200 e6.
   PubMed Web of Science ®Google Scholar
• Poyan Mehr A, Tran MT, Ralto KM, et al. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med. 2018;24(9):1351–1359.
   PubMed Web of Science ®Google Scholar